Novocure's Optune Gio fails Phase 3 TRIDENT trial in newly diagnosed glioblastoma; overall survival nearly identical in early-use vs. approved arm. Shares drop 17%.
June 18, 2026 09:11 AM EDT
Novocure’s electric fields therapy fails key glioblastoma study
Lei Lei Wu
News Reporter
Novocure reported Thursday morning that its electric fields device combined with chemoradiation failed to extend glioblastoma patients’ lives in a Phase …
Novocure's Phase 3 TRIDENT trial missed its primary survival endpoint in glioblastoma but confirmed TTFields safety.
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)
Elicio's KRAS cancer vaccine failed to cut recurrence or death vs. observation in a 144-patient Phase 2 trial, plunging shares…
Gilead and Merck end EVOKE-03 Trodelvy-Keytruda lung cancer study after missing PFS endpoint; oral lenacapavir-islatravir HIV…
Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to…
Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT® in Aggressive Brain Cancer (Glioblastoma)
